January 25, 2017 09:17 AM EST

Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters

John Carroll

Editor & Founder

One of the reasons why Novartis isn’t being forced to bid into the stratosphere for late-stage drugs is that its industry-topping R&D budget — $9 billion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Fight­ing a gener­ic on­slaught, No­var­tis adds CAR-T to its grow­ing list of late-stage block­busters

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters